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Abstract
Background: The human dopamine D4 receptor (DRD4) gene has been studied extensively as a
candidate gene for certain psychological traits and several behavioural and psychiatric disorders.
Both the 5' regulatory region and the coding sequence contain a number of polymorphisms. The
promoter variants have received particular attention in the past few years due to their possible role
in the regulation of gene transcription. Previously, the -521C/T SNP was shown to influence
promoter activity. The aim of this study is to perform an in-depth analysis of this effect in the
context of various neural cell lines.
Results:  Endogenous mRNA expression of the DRD4 gene was demonstrated in two
neuroblastoma (SK-N-F1, IMR32) and one retinoblastoma cell line (Y79) by RT-PCR. In addition,
very low DRD4 mRNA levels were also detected in HeLa cells. The transcriptional activity of a
series of 5' promoter deletion mutants was determined by transient transfection of luciferase
reporter constructs. The activity profile of these promoter fragments was similar in each of the cell
lines tested. The highest luciferase reporter activity was obtained with a construct containing
promoter sequences between nucleotides -668 to -389, while a putative silencer region was
localised spanning from nucleotide -1571 to -800. Surprisingly, the -521 C/T polymorphism had no
significant effect on transcriptional activity of the reporter construct with the highest activity (-668
to -389) in any of the three cell lines tested.
Conclusion: Our results do not confirm previous data assigning different transcriptional activities
to the -521 C/T alleles of the human DRD4 promoter. Furthermore, these findings highlight the
need for further characterization of the 5' regulatory region of the DRD4 gene and identification
of additional functional promoter polymorphic sites, especially in the context of haplotype.
Background
Dopamine, an important neurotransmitter in the brain,
plays a major role in the control of motor functions and
behavioral patterns via interacting with specific cell sur-
face receptors. Dopamine receptors belong to the large
family of G protein-coupled receptors and can be classi-
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fied as D1-like (D1, D5) and D2-like (D2, D3, D4) sub-
groups based on their sequence homology and
pharmacological characteristics [1]. The human
dopamine D4 receptor (DRD4) gene was originally
cloned by Van Tol et al. [2]. The 5' flanking region of the
gene was characterized by Kamakura et al. [3] as a house-
keeping gene-like promoter. The promoter lacks a TATA or
CAAT box but several putative transcription factor bind-
ing sites and CpG islands have been identified. 5'-RACE
analysis of DRD4 mRNA revealed multiple transcription
initiation sites located between nucleotides -501 and -
436, relative to the translational start site. The region
between -591 and -123 was found to contain the minimal
promoter and to confer tissue-specific expression on the
DRD4 gene and a putative repressor element was identi-
fied between nucleotides -770 and -679. Although high
DRD4 mRNA expression was detected in the limbic area
and frontal cortex associated with emotional function,
motivation and cognition, the highest mRNA level was
found in the retina [4]. The DRD4 plays an important role
in cognitive functions and it is a target of numerous antip-
sychotic drugs widely used in psychiatric disorders [5].
The 5' regulatory region and coding sequence of the
DRD4 gene harbour a number of polymorphisms which
may arise due to its telomeric location on chromosome
11. Promoter polymorphisms of the DRD4 gene, includ-
ing the 120 base pair (bp) duplication and several SNPs (-
521 C/T, -616 G/C SNP), have been extensively studied as
possible risk factors of psychological traits as well as
behavioural and psychiatric disorders. Despite the numer-
ous polymorphic allele variants, only one mutation has
been described in this region [6]. A 27 bp deleted
sequence was identified only in heterozygotes and with an
extremely low allele frequency. To assess the potential
functional role of the 27 bp deletion, an in silico analysis
was performed that revealed various transcription factor
binding sites within this short region.
An association between attention deficit hyperactivity dis-
order (ADHD) and the long form of the 120 bp duplica-
tion polymorphism was confirmed by a number of groups
[7-9], although contradictory results have been reported
by others [10]. Interestingly, the short form of this pro-
moter length polymorphism has been associated with
novelty seeking, a human personality trait sharing com-
mon characteristics with ADHD [11]. Seaman et al. [12]
identified several consensus transcription factor binding
sites within the 120 bp repeat, and there is in vitro evi-
dence for enhanced Sp1 binding capacity of the dupli-
cated form [13]. The functional role of these genetic
variants was studied recently employing in vitro luciferase
reporter assays, demonstrating a lower transcriptional
activity for the duplicated allele compared to the shorter
variant [14].
Another well studied polymorphism in the DRD4 regula-
tory region is the -616 C/G SNP, which is thought to inter-
act with the recently described -615 A/G variant in the
adjacent position [15]. It has been suggested that the -616
C/G SNP results in the creation of an AP-2 transcription
factor binding site [16]. An association of the -616 C/G
SNP with ADHD [17], schizophrenia [18] and personality
traits [19] have been reported in the literature but have
not been confirmed by others. Although there are no asso-
ciation studies concerning the -1217G insertion/deletion
polymorphism, its putative functional effect was exam-
ined by fMRI and a correlation was found between the
insertion allelic variant and a greater activation in the
anterior cingulate cortex, a brain area mediating conflict
[20].
One of the most studied polymorphisms of the DRD4
promoter region is the -521 C/T SNP. An association
between novelty seeking and the -521 CC genotype was
first identified in a Japanese population [21], followed by
a replication in a Caucasian (Hungarian) population [22],
although negative results have also been reported [23,24].
A recent meta-analysis showed a weak but positive associ-
ation between this polymorphism and novelty seeking
[25]. Lakatos et al. [26] revealed an association between
the infant disorganized attachment and the T allele of the
-521 C/T SNP but only in combination with the 7-repeat
form of the DRD4 exon III polymorphism. A family-based
association approach demonstrating a low-rate transmis-
sion of the DRD4 7-repeat – -521 T haplotype in a large
secure group of infants [27] supports this finding,
although results to the contrary have also been published
[28]. Furthermore, a positive association was detected
between the -521 C allele and schizophrenia [29], a disor-
der with elevated DRD4 mRNA levels in the frontal cortex
[30], although others failed to replicate this result [18]. A
weak relationship between the -521 C/T SNP and ADHD
has also been reported [17]. To date, only one study has
been performed that reveals the functional effect of the -
521 C/T SNP [29], using chloramphenicol acetyltrans-
ferase reporter assay with the minimal promoter previ-
ously defined in the Y79 retinoblastoma cell line. The
results from these experiments showed that the T allele
reduced promoter activity by 40% relative to the C allele.
In the present study, we attempted to replicate the possi-
ble transcriptional effect of the -521 C/T SNP using a sim-
ilar in vitro reporter system in a number of neuroblastoma
and retinoblastoma cell lines.
Results
DRD4 gene expression in neural and non-neural cell lines
Previous studies suggested a wide range of putative regu-
lator elements in the DRD4 promoter region that might
be involved in gene expression. To better characterize theBMC Molecular Biology 2006, 7:18 http://www.biomedcentral.com/1471-2199/7/18
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promoter, we performed luciferase assays in two neurob-
lastoma (SK-N-F1 and IMR32) and one retinoblastoma
(Y79) cell line. A non-neural cell line (HeLa) was also
included for comparison purposes. Prior to transcrip-
tional analysis, the cell lines were analysed for endog-
enous DRD4 gene expression. Figure 1 shows the
endogenous DRD4 mRNA levels in the four cell lines as
detected by RT-PCR. Significant expression of the DRD4
gene was demonstrated in SK-N-F1 and IMR32 neuroblas-
toma cells, as well as in Y79 retinoblastoma cell line (Fig-
ure 1). A low but measurable band was also detected in
HeLa cells, reflecting some DRD4 expression in this non-
neural cell line previously observed by others [14]. There
is an apparent difference in the mobility of the DRD4
transcripts in the HeLa and neural cell lines, likely result-
ing from the higher concentration of DRD4 transcripts in
the neural cell lines. In other experiments in which much
lower quantities of PCR product were loaded onto gels, no
mobility shift was observed and only a very faint band was
detected in case of HeLa (data not shown).
DRD4 promoter deletional analysis in transiently 
transfected neural and non-neural cell lines
To verify whether the region upstream of the transcription
start site has a repressor element between -770 and -679 –
as previously suggested by Kamakura et al. [3], a panel of
six 5' deletion mutants were created and cloned into the
pGL3 promoterless vector, upstream of the luciferase
reporter gene (Figure 2). Fragment A contained an 1183
bp sequence of the promoter region (-1571 to -389),
including the 120 bp duplication polymorphism. Frag-
ment B (-799 to -389) retained the putative negative mod-
ulator element, while fragment C (-668 to -389) lacked
this element. Fragments D, E and F had the same 5'
sequence as A, B and C, respectively, but included an extra
5' end region down to position -127. Fragments D, E and
F were similar to those used in the Japanese study [3] with
respect to the 5' UTR content. In all experiments, the pro-
moterless pGL3-Basic vector served as a negative control
Schematic representation depicting the location of the six 5' deletion mutant variants in the DRD4 gene promoter (pDRD4-A,  B, C, D, E and F) Figure 2
Schematic representation depicting the location of the six 5' deletion mutant variants in the DRD4 gene pro-
moter (pDRD4-A, B, C, D, E and F). The putative repressor region is indicated by a shaded box. The localization of sev-
eral important SNPs and the 120 bp duplication region are also shown. The arrow at -501 denotes the transcription start site.
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Expression analysis of the DRD4 gene by RT-PCR Figure 1
Expression analysis of the DRD4 gene by RT-PCR. β-
actin mRNA levels within the same extracts were used as an 
internal control. Note that the primers for the DRD4 gene 
were designed to span the exon 2 and exon 3 boundaries, to 
control for possible genomic DNA contamination.
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and pTK-luc, a herpes simplex virus thymidine kinase pro-
moter-containing vector, was used as a positive control.
Table 1 shows the relative luciferase activities of the differ-
ent constructs normalized to β-galactosidase activity.
Importantly, the pDRD4-B and C constructs exhibited the
highest reporter gene expression levels among the DRD4
promoter constructs in each cell line. By contrast, the rel-
ative ratios of the promoter activity of the pDRD4 con-
structs relative to the pTK-luc strong promoter-containing
construct, was much lower in HeLa cells than in cell lines
of neural origin. These data are in good agreement with
the results shown in Figure 1, indicating that endogenous
DRD4 expression levels correlate well with the luciferase
reporter activities.
The six constructs used here exhibited similar expression
patterns in each cell line (Figure 3). Surprisingly, the series
of pDRD4-D, E and F constructs exhibited no significant
transcriptional activity, while the pDRD4-A, B and C vec-
tors showed elevated levels in relation to the promoterless
vector (P < 0.05) (see Figure 3). Based on the data shown
in Table 1 and Figure 3, there was no significant difference
between the pDRD4-B and C vectors, which differed from
one another only by the presence (B) or absence (C) of the
putative repressor region. On the other hand, a signifi-
cantly reduced promoter activity of pDRD4-A could be
observed in each cell line when compared to construct B
(P < 0.001) (see Figure 3). This suggests that the negative
modulator sequence is located between positions -1571
and -800 as opposed to sequences -770 and -679, as pro-
posed earlier [3]. Despite the moderate transcriptional
activities of constructs pDRD4-D, E and F, their expression
pattern was very similar to that of pDRD4-A, B and C
respectively as measured in SK-N-F1 and Y79 cell lines.
Namely, the constructs containing the putative repressor
element located between positions -1571 and -800 (A and
D) showed significantly reduced transcriptional activity
compared to the vectors lacking this region (B, C and E, F,
see Table 1).
Effect of the -521 C/T SNP on transcriptional activity of 
DRD4 gene expression
For comparison of the relative promoter activity of the -
521 C and -521 T alleles, the pDRD4-C construct was cho-
sen as the parent plasmid since it exhibited the strongest
transcriptional activity in all cell lines tested. After tran-
sient transfection of these DNAs into SK-N-F1, Y79 and
IMR32 cells, a high level of luciferase activity was
observed for each SNP construct relative to the promoter-
less pGL3 control vector (Figure 4). Nevertheless, under
the conditions applied in these experiments, we could not
detect any significant differences between the transcrip-
tional activities of the pDRD4-C constructs possessing
either the -521 C or T alleles in any of these cell lines.
Discussion
Regulation of DRD4 gene expression is a significant issue,
not only due to the well-known importance of this neuro-
transmitter receptor in brain function, but also because its
highly polymorphic promoter has been implicated in a
number of psychogenetic association studies. The human
Y79 and IMR32 neuroblastoma cell lines reportedly
express DRD4 mRNA [3]. In addition to these cells,
another neuroblastoma cell line (SK-N-F1) was also
shown to produce high level of DRD4 mRNA in our study
(Figure 1). These results are in agreement with the expres-
sion pattern of the DRD4 mRNA described by Van Tol et
al [2]. A low but detectable level of DRD4 mRNA was also
observed in HeLa cells, indicating that the DRD4 pro-
moter was slightly active in this cell line, in agreement
with recent results [14], but in contrast to earlier data [3].
To characterize the DRD4 promoter, Kamakura et al. [3]
performed CAT reporter assays using IMR32, Y79 and
HeLa cell lines, and identified a putative promoter region
between nucleotides -591 and -123 conferring tissue-spe-
cific DRD4 expression. In addition, a short region located
1.2 kb upstream from the initiation codon that harbours
the 120 bp duplication, has also been shown to exhibit
promoter activity [14]. Notably, we could not map any
Table 1: Relative luciferase activity of the DRD4 promoter constructs. Luciferase activities of the crude cell extracts were normalized 
to their β-galactosidase activities. Data are shown as the mean ± SD. Results of a representative experiment are shown as measured in 
triplicates. Similar data were obtained from three independent transfection experiments.
Luciferase/β-gal ratio SK-N-F1 Y79 IMR32 HeLa
pGL3-Basic 3.52 ± 1.43 3.87 ± 0.09 3.70 ± 0.29 3.59 ± 0.13
pDRD4-A 10.35 ± 1.00 8.80 ± 1.29 6.77 ± 0.86 8.71 ± 0.78
pDRD4-B 31.63 ± 4.7 26.89 ± 4.51 10.56 ± 0.52 27.08 ± 1.54
pDRD4-C 34.09 ± 3.34 28.98 ± 4.61 9.45 ± 0.46 21.89 ± 0.99
pDRD4-D 0.42 ± 0.02 1.75 ± 0.15 1.97 ± 0.12 2.56 ± 0.14
pDRD4-E 1.66 ± 0.20 4.18 ± 0.38 1.76 ± 0.22 2.51 ± 0.31
pDRD4-F 1.75 ± 0.17 4.21 ± 0.23 1.77 ± 0.16 2.63 ± 0.30
pTK-luc 84.21 ± 10.76 114.97 ± 10.50 28.73 ± 2.29 172.35 ± 2.05BMC Molecular Biology 2006, 7:18 http://www.biomedcentral.com/1471-2199/7/18
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region with cell type-specific transcriptional activity in our
experimental system, as the in vitro transcriptional activity
of the six promoter constructs showed a similar expres-
sion pattern in all cell lines, including the non-neural
HeLa cells (Figure 3). It is important to note, however,
that a cell type-specific feature is often typical for mem-
bers of the dopamine receptor family [31-36], indicating
the need for additional studies that explore tissue-specific
DRD4 expression in experimental systems that more
closely mimic in vivo conditions.
In terms of transcriptional activity, our constructs could
be classified into two main groups: the pDRD4-D, E and
F group exhibited about 10 fold lower activity than the
pDRD4-A, B and C group. In fact, plasmids pDRD4-D, E
and F possessed similar or even lower activities than the
promoterless pGL3-Basic vector (see Table 1). These
results were quite surprising since the D, E and F frag-
ments were very similar to those used in a former study
[3]. A possible explanation for the inactivity of these pro-
moter fragments could be due to the existence of four ATG
codons residing with in this region (nucleotides -389 and
-127) at positions -361, -346, -261 and -163. Three of
these start codons are out of reading frame and could lead
to the formation of a frame-shifted (inactive) luciferase
The effect of 5' deletions on the transcriptional activity of the DRD4 promoter in four different cell lines Figure 3
The effect of 5' deletions on the transcriptional activity of the DRD4 promoter in four different cell lines. Signif-
icant difference in promoter activity of pDRD4-A could be observed in each cell line relative to construct B (P < 0.001). Luci-
ferase activity was normalized to the β-galactosidase activity. Data are expressed as fold increments over the pGL3-Basic 
activity and shown as mean ± SD. Results of a representative experiment are shown as measured in triplicates (*P < 0.05, **P 
< 0.01, ***P < 0.001 versus the corresponding promoterless vector in each cell type.) Similar data were obtained from three 
independent transfection experiments.
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gene. Another possibility is that a strong negative modu-
lator element resides in this region.
The comparative analysis of constructs pDRD4-B (-799 to
-389) and pDRD4-C (-668 to -389) was particularly inter-
esting in light of a silencer region mapped to positions -
770 and -679 by Kamakura et al. [3]. We observed no sig-
nificant difference between the transcriptional activities of
constructs with (pDRD4-B) or without (p-DRD4-C) the
previously identified silencer region (see Figure 3 and
Table 1). On the other hand, a significant difference was
found between the in vitro transcriptional activity of
pDRD4-B (-799 to -389) and pDRD4-A (-1571 to -389),
suggesting the presence of a negative modulator in the
region between positions -1571 and -800. Thus, the tran-
scriptional activity data generated with constructs A, B and
C has revealed yet another silencer region upstream from
the one previously described [3]. Together, these results
suggest that the human DRD4 gene promoter may possess
two negative modulator regions, one of which did not
function in our system. This hypothesized structure of the
gene is reminiscent of that of the rat D2-, the Drosophila
Dmdop1-, as well as the rat D3 dopamine receptor gene
structure, which all contain two inhibitory elements in
their promoter [32,37,38]. Nevertheless, the dopamine
receptor promoters also show remarkable heterogeneity
in their 5'-untranslated region. For example, the Dro-
sophila Dmdop1 and the rat D2 dopamine receptor pro-
moter contain an additional activating region beside the
silencing elements [35,37]. Similarly, the human D1A
and D5 dopamine receptor genes also comprise varying
numbers of positive and negative modulator elements
[31,34]. Beside the regulatory elements, the precise
boundaries of the DRD4 promoter remain poorly
defined. One study suggested that the promoter region
might be within an intronic region [39]. This theory was
based on previously reported discrepancies in the size of
the DRD4 mRNA which was originally reported as 5.3 kb
in the SK-N-MC human neuroblastoma cell line and in
the striatum, medulla, frontal cortex and limbic area of
the rat and monkey brain [2]. By contrast, the DRD4
mRNA was later found to be much shorter (1.5 kb), and
expressed at higher levels, in the corpus callosum,
medulla, subthalamic nucleus, as well as in the mesolim-
bic system and related regions. Furthermore, the DRD4
mRNA was barely detected in the striatum and the cere-
bral cortex [40] in contrast to the previous findings [2].
These observed differences in mRNA size suggest that the
DRD4 gene might have alternative transcription start sites,
as in the case of the catechol-O-methyltransferase
(COMT) gene, resulting in the formation of two distinct
transcripts with differing 5' ends [41]. Additionally, Todd
and O'Malley suggested the possibility that a large intron
might separate the coding exons of the DRD4 gene from
the untranslated exons [39], as described for the
dopamine D2 [35,36,42] and D3 [32] receptors. In con-
clusion, the 5' untranslated region of the dopamine D4
receptor shows a high degree of complexity, emphasizing
the need for further characterization to better define the
core promoter and transcription initiation site.
Another aim of our study was to corroborate the effect of
the -521 C/T SNP on the transcriptional activity previ-
ously described by Okuyama et al. [21,29] however, in
our system we observed no significant difference between
the activities of the -521 C and -521 T alleles, in either the
The effect of the -521 C/T SNP on the transcriptional activity of the DRD4 minimal promoter in neural cell lines Figure 4
The effect of the -521 C/T SNP on the transcriptional activity of the DRD4 minimal promoter in neural cell 
lines. No significant difference could be detected between the transcriptional activities of the pDRD4-C constructs possessing 
the -521 C or T alleles in any of these cell lines. Luciferase activity was normalized to the β-galactosidase activity. Data are pre-
sented as fold increments over the pGL3-Basic activity and shown as mean ± SD. Results of a representative experiment are 
shown as measured in triplicates. Similar data were obtained from three independent transfection experiments.
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neuroblastoma or retinoblastoma cell lines (Figure 4).
There were several differences in experimental setup
between the previous and the present study, such as
applying different reporter vectors and some variation in
the length of the promoter fragment. The length of the
cloned promoter fragments especially might have a signif-
icant effect on transcriptional activity [43]. An additional
possibility for these conflicting results is the highly poly-
morphic nature of this gene. Other identified polymor-
phisms in the DRD4 promoter region, such as the SNPs in
positions -768, -616, -615, -603 and -600, may also influ-
ence promoter activity. For this reason, a novel approach
for elucidating the effect of these various polymorphisms
on DRD4 gene expression would be to perform a compar-
ative analysis of the SNPs in combination in the context
of different genetic haplotypes.
Conclusion
The aim of this study was to evaluate the effect of the -521
C/T SNP on DRD4 promoter activity. Our results do not
confirm previous data assigning different transcriptional
activities to the -521 C/T alleles in any of the three neuro-
nal cell lines tested. The transcriptional activity of a series
of 5' promoter deletion mutants was determined by luci-
ferase reporter system. This experiments revealed a puta-
tive silencer region located between positions -1571 and -
800.
Methods
Plasmid constructs
Six overlapping fragments were amplified by PCR from
the promoter of the DRD4 gene using the following prim-
ers containing either an XhoI or an HindIII recognition
site: DR4-S1 (5' acc act cga gtg ggc tgg act cgc cgt ttg gc 3',
corresponding to region -1571/-1550; translation start
site is referred to as position +1), DR4-S2 (5' aag gct cga
gcc cgg gac ccc ctg ccc agg 3', -799/-780), DR4-S3 (5' ggt tct
cga gaa ctg tgc aac ggg tgg ggc cg 3', -668/-647), DR4-AS1
(5' aag gaa gct tcc ctc ggg cgc tca ccc tag tcc 3', -389/-411),
and DR4-AS2 (5' aag gaa gct tcc cgc ggc gct cca ccg tga 3',
-127/-146). The reaction mixture contained 10 ng of
genomic DNA, 1-1 µM of each primer, 1 U Pfu  DNA
polymerase (MBI Fermentas), 1x Pfu PCR buffer, 0.2 mM
dNTP-mix, 1x solution Q (Qiagen) and the final MgSO4
concentration was set to 2.5 mM in a final volume of 10
µl. Amplification began with a 3 min denaturation step at
95°C followed by 35 cycles of 1 min denaturation at
94°C and 3 min annealing/synthesis at 72°C. A final
extension step was applied at 72°C for 10 min. The ampli-
fied products were digested with HindIII and XhoI and
cloned into the luciferase reporter plasmid pGL3-Basic
(Promega). After transformation into E. coli DH5α, all the
plasmids were purified with Qiagen Plasmid Midi Kit.
Constructs were verified by sequencing. The -521 C/T alle-
les were generated using the QuickChange Site-Directed
Mutagenesis Kit (Stratagene). The primers used were 5' ggc
gtg gag ggtgcg cac gag gtc 3' (forward, -532/-509) and 5'
gac ctc gtg cgc acc ctc cac gcc 3' (reverse, -509/-532) for -
521C site to T and 5' ggc gtg gag ggcgcg cac gag gtc 3' (for-
ward, -532/-509) and 5' gac ctc gtg cgc gcc ctc cac gcc 3'
(reverse, -509/-532) for -521T to C site. The mutations
were confirmed by sequencing.
Total RNA isolation, RT-PCR
Total RNA was isolated from neural and HeLa cells using
the TRIzol reagent (Invitrogen) according to the manufac-
turer's procedure. The reaction contained 3 µg of total
RNA, 0.2 µg random hexameric primers (Promega), 8 U
RNasin (Promega) and DEPC-treated water in a final vol-
ume of 10 µl. The reaction mixture was heated to 70°C for
4 min, followed by the addition of 4 µl M-MuLV of reverse
transcriptase 5x reaction buffer (Fermentas), 24 U RNasin,
0.5 mM dNTPs, 100 U RevertAid M-MuLV reverse tran-
scriptase (Fermentas) and DEPC-treated water to final vol-
ume of 20 µl total. The reaction was incubated at 37°C for
40 min followed by 42°C for 20 min and 99°C for 5 min.
Single-stranded cDNAs were amplified by DRD4 specific
primers DART-3 (5' gca ccg cct cca tct tca acc 3') and
DART-4 (5' cgg aac gtg gcc cag tag agc 3') in a final volume
of 10 µl containing 1 µl of RT reaction mix, 1 µM of each
primer, 5 U HotStarTaq DNA-polymerase, 1x HotStar PCR
buffer, 1x Q solution and 0.2 mM dNTPs (Qiagen). Ther-
mocycling conditions were as follows: incubation at 95°C
for 15 min followed by 32 cycles of 94°C for 1 min, 68°C
for 1 min and 72°C for 1 min completed with a final
extension step at 72°C for 10 min. As described earlier,
human β-actin gene served as an internal control [44].
PCR products were electrophorised in a 2% agarose gel.
Cell culture
The human neuroblastoma cell line IMR32 and HeLa cells
were cultured in minimal essential medium Eagle (Gibco)
supplemented with 10 % fetal bovine serum, 1% nones-
sential amino acids and 1% Na-pyruvate. The human
retinoblastoma Y79 cells were maintained in RPMI 1640
medium (Sigma) supplemented with 20 % fetal bovine
serum and 1% Na-pyruvate. SK-N-F1 (neuroblastoma)
cells were grown in Dulbecco's modified Eagle's medium,
High Glucose (Gibco) supplemented with 10 % fetal
bovine serum and 1% nonessential amino acids. All cell
lines were grown at 37°C with 5% CO2.
Transient transfections
SK-N-F1 transfection was performed by the calcium phos-
phate-DNA coprecipitation method. A total of 1.2 × 106
cells were seeded 24 h prior to transfection in six-well
plates. Equimolar amounts of reporter plasmids (~ 5 µg)
together with 2.5 µg internal control plasmid pCMV-β-gal
were introduced into the cells. The calcium phospate pre-
cipitate was washed out 14 h after transfection and theBMC Molecular Biology 2006, 7:18 http://www.biomedcentral.com/1471-2199/7/18
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cells were harvested 36 hours later and lysed in 100 µl of
250 mM Tris-HCl pH 8.0. HeLa cells were transfected with
Lipofectamine 2000 (Invitrogen). A mixture of 1.7–2.0 µg
reporter construct and 0.2 µg pCMV-β-gal and 6 µl Lipo-
fectamine 2000 was used to transfect 0.4 × 106 cells plated
24 h before transfection in six-well plates. Y79 and IMR32
transfections were performed in 12 well plates. Approxi-
mately 1.6 × 106 cells (Y79) or 1.35 × 106 cells (IMR32)
were plated 24 h before transfection and transfected with
equimolar amounts of reporter plasmids (1.7–2.0 µg), 1
µg pCMV-β-gal combined with 4 µl Lipofectamine Rea-
gent and 4 µl Plus Reagent (Invitrogen). In the case of
HeLa, Y79 and IMR32 cells, 1–1.2 ml fresh medium was
added after 5 hours of incubation, and the cells were
allowed to grow for 48 h before harvesting.
Luciferase and β-galactosidase assays
Cells were extracted by three consecutive freeze-thaw
cycles and subsequent centrifugation. Supernatants were
used for enzyme activity determinations. Luciferase and β-
galactosidase activities were detected using the Luciferase
Assay System kit (Promega) and by ONPG (o-nitrophe-
nyl-β-D-galactopyranoside) cleavage rate, respectively.
Luminescence was measured using a Mithras LB940 mul-
tilabel reader (Berthold Technologies, Bad Wildbad, Ger-
many). Luciferase promoter activities were normalized to
β-galactosidase activities. Three paralels were used in all
transfections and all experiments were performed in trip-
licate.
Statistical analysis
Statistical analysis was performed with one-way ANOVA
followed by the Tukey-Kramer Multiple Comparison Test
(GraphPad InStat).
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